PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
OSL:PHO - Euronext Oslo - NO0010000045 - Common Stock - Currency: NOK
PHO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 53 industry peers in the Pharmaceuticals industry. PHO has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PHO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PHO had negative earnings in the past year.
In the past year PHO had a positive cash flow from operations.
In the past 5 years PHO reported 4 times negative net income.
Of the past 5 years PHO 4 years had a positive operating cash flow.
1.2 Ratios
PHO has a Return On Assets of 0.30%. This is in the lower half of the industry: PHO underperforms 66.04% of its industry peers.
PHO's Return On Equity of 0.45% is on the low side compared to the rest of the industry. PHO is outperformed by 66.04% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.79%, PHO is doing worse than 66.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROIC | 1.79% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHO has a Profit Margin of 0.40%. This is in the lower half of the industry: PHO underperforms 64.15% of its industry peers.
PHO has a Operating Margin of 2.64%. This is in the lower half of the industry: PHO underperforms 64.15% of its industry peers.
In the last couple of years the Operating Margin of PHO has declined.
PHO's Gross Margin of 93.97% is amongst the best of the industry. PHO outperforms 94.34% of its industry peers.
In the last couple of years the Gross Margin of PHO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHO is destroying value.
Compared to 1 year ago, PHO has about the same amount of shares outstanding.
PHO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHO has an improved debt to assets ratio.
2.2 Solvency
PHO has an Altman-Z score of 5.75. This indicates that PHO is financially healthy and has little risk of bankruptcy at the moment.
PHO has a better Altman-Z score (5.75) than 84.91% of its industry peers.
There is no outstanding debt for PHO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.75 |
ROIC/WACC0.21
WACC8.52%
2.3 Liquidity
A Current Ratio of 3.81 indicates that PHO has no problem at all paying its short term obligations.
PHO has a Current ratio of 3.81. This is amongst the best in the industry. PHO outperforms 94.34% of its industry peers.
A Quick Ratio of 3.44 indicates that PHO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.44, PHO belongs to the best of the industry, outperforming 96.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
The earnings per share for PHO have decreased strongly by -156.82% in the last year.
Looking at the last year, PHO shows a small growth in Revenue. The Revenue has grown by 4.94% in the last year.
PHO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.29% yearly.
EPS 1Y (TTM)-156.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)4.94%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%9.54%
3.2 Future
Based on estimates for the next years, PHO will show a very strong growth in Earnings Per Share. The EPS will grow by 190.44% on average per year.
The Revenue is expected to grow by 14.98% on average over the next years. This is quite good.
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHO. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 31.09, which means the current valuation is very expensive for PHO.
Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than the industry average as 67.92% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.21, PHO is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 31.09 |
4.2 Price Multiples
69.81% of the companies in the same industry are cheaper than PHO, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHO is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.5 | ||
| EV/EBITDA | 35.03 |
4.3 Compensation for Growth
PHO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHO's earnings are expected to grow with 190.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y264.59%
EPS Next 3Y190.44%
5. Dividend
5.1 Amount
No dividends for PHO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (8/1/2025, 7:00:00 PM)
63.2
-2.1 (-3.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.92%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.71B
Analysts82.5
Price Target79.05 (25.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-94.41%
Min EPS beat(2)-203.96%
Max EPS beat(2)15.13%
EPS beat(4)2
Avg EPS beat(4)-37.97%
Min EPS beat(4)-203.96%
Max EPS beat(4)47.82%
EPS beat(8)5
Avg EPS beat(8)40.12%
EPS beat(12)6
Avg EPS beat(12)-9.06%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.7%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)-2.17%
Revenue beat(4)1
Avg Revenue beat(4)-3.95%
Min Revenue beat(4)-9.78%
Max Revenue beat(4)1.4%
Revenue beat(8)3
Avg Revenue beat(8)-3.64%
Revenue beat(12)6
Avg Revenue beat(12)-2.7%
Revenue beat(16)7
Avg Revenue beat(16)-4.28%
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)-155%
EPS NQ rev (3m)-155%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)-6.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 31.09 | ||
| P/S | 3.22 | ||
| P/FCF | 26.5 | ||
| P/OCF | 22.63 | ||
| P/B | 3.63 | ||
| P/tB | 7.26 | ||
| EV/EBITDA | 35.03 |
EPS(TTM)-0.25
EYN/A
EPS(NY)2.03
Fwd EY3.22%
FCF(TTM)2.38
FCFY3.77%
OCF(TTM)2.79
OCFY4.42%
SpS19.64
BVpS17.4
TBVpS8.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROCE | 2.32% | ||
| ROIC | 1.79% | ||
| ROICexc | 3.13% | ||
| ROICexgc | 9.81% | ||
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% | ||
| FCFM | 12.14% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score5
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.09% | ||
| Cap/Sales | 2.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 175.53% | ||
| Profit Quality | 3024.79% | ||
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 5.75 |
F-Score5
WACC8.52%
ROIC/WACC0.21
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-156.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue 1Y (TTM)4.94%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%9.54%
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
EBIT growth 1Y-61.13%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year105.28%
EBIT Next 3Y59.66%
EBIT Next 5YN/A
FCF growth 1Y1030.99%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y590.65%
OCF growth 3Y47.56%
OCF growth 5Y30.02%